Piper Jaffray Raises Price Target on Insulet (PODD) to $41 Following 2Q Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Insulet Reports Second Quarter 2015 Financial Results
August 12, 2015 4:01 PM EDTBILLERICA, Mass., Aug. 12, 2015 /PRNewswire/ -- Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced financial results for the three months ended June 30, 2015.       Â
Second Quarter Highlights and Recent Developments:
Second quarter financial results: Total revenue of $75.6 million exceeds Company's prior expectations of $67 to $70 million. U.S. OmniPod revenue of $44.7 million. International OmniPod revenue of $7.7 million. Drug Delivery revenue of $7.5 million. Neighborhood Diabetes revenue of $15.7 million. Announced today appointment of Michael... More